Stock & Company Details
Inhibikase Therapeutics Inc $IKT
Price:
46,691,331
132M
$268M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-0.60
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
IKT technical indicators
Latest Inhibikase Therapeutics Inc (IKT) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
63.03 16.5%
MACD:
0.06 5.7%
SMA 50:
$1.80 0.1%
SMA 200:
$1.71 0.1%
EMA 20:
$1.82 0.7%
Bollinger Bands:
2.02 / 1.52
Stochastic:
86.32 10.4%
ADX 14:
24.36 12.1%
ATR 14:
0.10 9.0%
CCI 20:
132.27 19.6%
OBV:
32.24M 2.8%
ROC 12:
16.17% 25.0%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Finance Bot
Ask your questions
Start by typing a question below.
